Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study

被引：0
|
作者：
Lucheng ZHU
Changlin Zou
Zhanchun Zhang
Jianfang Wang
Li Yang
Chuangzhou Rao
Zhiping Yang
Jiafeng Liang
Bing Xia
M. A. Shenglin
机构：
[1] Affiliated Hangzhou Cancer Hospital,Department of Thoracic Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province
[2] Zhejiang University School of Medicine,Department of Radiotherapy
[3] The First Affiliated Hospital of Wenzhou Medical University,Department of Radiotherapy
[4] Ningbo Medical Center Lihuili Hospital,Department of Radiotherapy, Shaoxing People’s Hospital (Shaoxing Hospital
[5] Zhejiang University School of Medicine),Department of Pulmonary & Critical Care Medicine, Shulan (Hangzhou) Hospital
[6] Affiliated to Zhejiang Shuren University Shulan International Medical college,Department of Radiotherapy & Chemotherapy,Hwa Mei Hospital
[7] University of Chinese Academy of Sciences,Department of Oncology, Affiliated Hospital of Jiaxing University
[8] The First Hospital of Jiaxing,Department of Oncology
[9] Jiande Second People’s Hospital,Department of Cancer Medical Center
[10] Affiliated Xiaoshan Hospital,undefined
[11] Hangzhou Normal University,undefined
来源：
BMC Cancer | / 21卷
关键词：
Almonertinib; EGFR-TKI; Radiotherapy; Locally advanced NSCLC; Radiation pneumonitis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study
    Zhu, Lucheng
    Zou, Changlin
    Zhang, Zhanchun
    Wang, Jianfang
    Yang, Li
    Rao, Chuangzhou
    Yang, Zhiping
    Liang, Jiafeng
    Xia, Bing
    Shenglin, M. A.
    BMC CANCER, 2021, 21 (01)
  • [2] Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer
    Furuse, K
    Fukuoka, M
    Kawahara, M
    Nishikawa, H
    Takada, Y
    Kudoh, S
    Katagami, N
    Ariyoshi, Y
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 2692 - 2699
  • [3] Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer
    Sequist, L. V.
    Soria, J-C
    Goldman, J. W.
    Wakelee, H. A.
    Gadgeel, S. M.
    Varga, A.
    Papadimitrakopoulou, V.
    Solomon, B. J.
    Oxnard, G. R.
    Dziadziuszko, R.
    Aisner, D. L.
    Doebele, R. C.
    Galasso, C.
    Garon, E. B.
    Heist, R. S.
    Logan, J.
    Neal, J. W.
    Mendenhall, M. A.
    Nichols, S.
    Piotrowska, Z.
    Wozniak, A. J.
    Raponi, M.
    Karlovich, C. A.
    Jaw-Tsai, S.
    Isaacson, J.
    Despain, D.
    Matheny, S. L.
    Rolfe, L.
    Allen, A. R.
    Camidge, D. R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (18): : 1700 - 1709
  • [4] Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer
    He, Yong
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (06): : 578 - 578
  • [5] A Phase II Study of Gefitinib With Concurrent Thoracic Radiotherapy in Patients With Unresectable, Stage III Non-small-cell Lung Cancer Harboring EGFR Mutations (WJOG6911L)
    Akamatsu, Hiroaki
    Harada, Hideyuki
    Tokunaga, Shoji
    Yoshimura, Naruo
    Ikeda, Hiroko
    Oizumi, Satoshi
    Sugimoto, Naotoshi
    Takano, Toshimi
    Murakami, Haruyasu
    Nishimura, Yasumasa
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    CLINICAL LUNG CANCER, 2019, 20 (01) : E25 - E27
  • [6] Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer
    Sekine, I
    Noda, K
    Oshita, F
    Yamada, K
    Tanaka, M
    Yamashita, K
    Nokihara, H
    Yamamoto, N
    Kunitoh, H
    Ohe, Y
    Tamura, T
    Kodama, T
    Sumi, M
    Saijo, N
    CANCER SCIENCE, 2004, 95 (08) : 691 - 695
  • [7] Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in stage III non-small-cell lung cancer
    Wu, HG
    Bang, YJ
    Choi, EK
    Ahn, YC
    Kim, YW
    Lim, TH
    Suh, C
    Park, K
    Park, CI
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 52 (01): : 75 - 80
  • [8] PHASE-II STUDY OF CONCURRENT RADIOTHERAPY AND CHEMOTHERAPY FOR UNRESECTABLE STAGE-III NON-SMALL-CELL LUNG-CANCER
    FURUSE, K
    KUBOTA, K
    KAWAHARA, M
    KODAMA, N
    OGAWARA, M
    AKIRA, M
    NAKAJIMA, S
    TAKADA, M
    KUSUNOKI, Y
    NEGORO, S
    MATSUI, K
    MASUDA, N
    TAKIFUJI, N
    KUDOH, S
    NISHIOKA, M
    FUKUOKA, M
    JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (04) : 869 - 875
  • [9] Adjuvant Osimertinib in EGFR-Mutated Non-Small-Cell Lung Cancer
    Planchard, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18): : 1780 - 1782
  • [10] Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
    Wu, Yi-Long
    Tsuboi, Masahiro
    He, Jie
    John, Thomas
    Grohe, Christian
    Majem, Margarita
    Goldman, Jonathan W.
    Laktionov, Konstantin
    Kim, Sang-We
    Kato, Terufumi
    Vu, Huu-Vinh
    Lu, Shun
    Lee, Kye-Young
    Akewanlop, Charuwan
    Yu, Chong-Jen
    de Marinis, Filippo
    Bonanno, Laura
    Domine, Manuel
    Shepherd, Frances A.
    Zeng, Lingmin
    Hodge, Rachel
    Atasoy, Ajlan
    Rukazenkov, Yuri
    Herbst, Roy S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18): : 1711 - 1723
12345